Danica Collins is a diabetes health and wellness coach, and she has lived with type 1 diabetes herself for over 17 years. Here she shares how and why she uses inhaled insulin Afrezza in her daily diabetes management.
[read_more text="read more" title="read more" url="https://tcoyd.org/2023/03/danica-the-diabetic-on-why-she-uses-afrezza-inhaled-insulin/" align="left"]
TCOYD’s newest intern was diagnosed with type 1 diabetes at a young age, but his diagnosis ultimately gave him the foundation and passion to pursue a career in healthcare in order to help others living with the condition.
[read_more text="read more" title="read more" url="https://tcoyd.org/2023/03/from-fear-to-focus-how-t1d-shaped-my-future/" align="left"]
Dr. E shares a case study from an MDI LADA patient, pointing out successes in his regimen along with recommendations for improvement.
[read_more text="read more" title="read more" url="https://tcoyd.org/2023/01/what-can-we-learn-from-this-lada-patient-who-chose-mdi-over-pump-therapy/" align="left"]
History has just been made! The FDA recently approved a new treatment therapy called Tzield that works to prevent or delay the onset of type 1 diabetes. People at a high risk of developing type 1 can now delay its onset for years, giving them valuable time to learn about the condition and how to manage it safely.
[read_more text="read more" title="read more" url="https://tcoyd.org/2022/11/fda-approves-tzield-to-prevent-or-delay-the-onset-of-type-1-diabetes/" align="left"]
Vertex Pharmaceuticals is relatively new to the type 1 diabetes space, and they are working hard to understand what it’s like for people to live with T1D so they can develop transformative therapies. They’re currently investigating and advancing cell therapies aimed at treating an underlying cause of type 1 – the absence of insulin-producing cells.
[read_more text="read more" title="read more" url="https://tcoyd.org/2022/10/vertex-pharmaceuticals-committed-to-understanding-life-with-t1d/" align="left"]
